Lungenstudie AcceleRET zu Pralsetinib bei 1L-RET-fusionspositivem metastatischem NSCLC

AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC

  • Krebs
  • Tumor
  • Neoplasien
  • Atemwegs Neoplasien
  • Lungenkrebs
  • RET-fusion Non Small Cell Lung Cancer
  • Stammzell- und embryonale Neoplasien
  • Nicht-kleinzelliges Lungenkarzinom
  • Lungenneoplasie
  • Bronchogenes Karzinom
  • Nervengewebsneoplasie
  • Thorakale Neoplasien
  • Kopf-Hals-Karzinom
  • Neoplasien im Kopf- und Halsbereich
Bitte beachten Sie, dass der Rekrutierungsstatus der Studie an Ihrem Standort vom Gesamtstatus der Studie abweichen kann, da einige Studienzentren früher rekrutieren als andere.
Status der Studie:

Abgeschlossen

Diese Studie läuft in
Städte
  • Dresden
  • Gauting
  • Oldenburg
  • Schweinfurt
  • Stuttgart
Studien-ID:

NCT04222972 2019-002463-10 BLU-667-2303 2023-505035-12-00 BO42864

      Studienzentren finden

      Die folgenden Informationen stammen aus der öffentlich zugänglichen Website ClinicalTrials.gov und werden für Laien bearbeitet.

      Die folgenden Informationen stammen aus der öffentlich zugänglichen Website ClinicalTrials.gov und werden nicht geändert.

      Results Disclaimer

      Studienzusammenfassung

      This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for participants with RET fusion-positive metastatic NSCLC who have not previously received systemic anticancer therapy for metastatic disease. Participants who have centrally confirmed progressive disease on the control arm have the option to crossover to pralsetinib.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT04222972, BO42864, 2019-002463-10,BLU-667-2303,2023-505035-12-00 Studien-ID
      Pralsetinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab, Gemcitabine, Paclitaxel, Nab-Paclitaxel Treatments
      RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Diseases, Head and Neck Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue Condition
      Official Title

      A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer

      Einschlusskriterien

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participant has pathologically confirmed, definitively diagnosed, locally advanced (not able to be treated with surgery or radiotherapy) or metastatic NSCLC and has not been treated with systemic anticancer therapy for metastatic disease.
      • Participant must have a documented RET-fusion
      • Participant has measurable disease based on RECIST 1.1 as determined by the local site Investigator/radiology assessment.
      • Participant has an ECOG Performance Status of 0 or 1.
      • Participant should not have received any prior anticancer therapy for metastatic disease.
      • Participants can have received previous anticancer therapy (except a selective RET inhibitor) in the neoadjuvant or adjuvant setting but must have experienced an interval of at least ≥ 6 months from completion of therapy to recurrence.
      • Participants that received previous immune checkpoint inhibitors in the adjuvant or consolidation following chemoradiation are not allowed to receive pembrolizumab if randomized in Arm B
      • Participant is an appropriate candidate for and agrees to receive 1 of the Investigator choice platinum-based chemotherapy regimens if randomized to Arm B.
      • For women of childbearing potential: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use contraception.
      • For men: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use a condom and agree to refrain from donating sperm.
      Exclusion Criteria
      • Participant's tumor has any additional known primary driver alterations other than RET, such as targetable mutations of EGFR, ALK, ROS1, MET, and BRAF. Investigators should discuss enrollment with Sponsor designee regarding co-mutations.
      • Participant previously received treatment with a selective RET inhibitor.
      • Participant received radiotherapy or radiosurgery to any site within 14 days before randomization or more than 30 Gy of radiotherapy to the lung in the 6 months before randomization.
      • Participant with a history of pneumonitis within the last 12 months.
      • Participant has CNS metastases or a primary CNS tumor that is associated with progressive neurological symptoms or requires increasing doses of corticosteroids to control the CNS disease. If a participant requires corticosteroids for management of CNS disease, the dose must have been stable for the 2 weeks before Cycle 1 Day 1.
      • Participant has had a history of another primary malignancy that has been diagnosed or required therapy within the past 3 years prior to randomization.

      Um die aktuellste Version dieser Seite aufzurufen gehen Sie bitte auf www.Klinische-studien-für-patienten.de

       

      Über klinische Studien

      Erfahren Sie mehr über klinische Studien und wie sie durchgeführt werden

      Erfahren Sie mehr